A large group of U.S. states accused key players in the generic drug industry of a broad price-fixing conspiracy, moving on Tuesday to widen an earlier lawsuit to add many more drug makers and medicines in an action that sent some company shares tumbling.
The lawsuit, brought by the attorneys general of 45 states and the District of Columbia, accused 18 companies and subsidiaries and named 15 medicines. It also targeted two individual executives: Rajiv Malik, president and executive director of Mylan NV; and Satish Mehta, CEO and managing director of India's Emcure Pharmaceuticals.
Shares of Pennsylvania-based Mylan, also named as a defendant, fell more than 6 percent after the news.